Common Sense in Oncology

Bishal Gyawali, MD, PhD, is an associate professor in the Department of Public Health Sciences, a scientist in the Division of Cancer Care and Epidemiology, and an attending physician in the Department of Medical Oncology at Queen's University in Kingston, Ontario, Canada, and is also affiliated faculty at the Program on Regulation, Therapeutics, and Law in the Department of Medicine at Brigham and Women's Hospital in Boston. His clinical and research interests revolve around cancer policy, global oncology, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, and supportive care.

+ Add to Email Alerts

When a Cancer Drug Shortens Life: Lessons From ARIEL4 Dr Gyawali unpacks the ARIEL4 trial, in which a cancer drug shortened survival by 6 months. What went wrong, and what can we learn to prevent future harm?
Medscape Oncology, March 25, 2025
Why Overall Survival Should Be The Oncology Trial Endpoint Bishal Gyawali, MD, PhD, and Sharon Batt, PhD, explore why overall survival continues to be the most patient-centric marker of clinical benefit.
Medscape Oncology, January 23, 2025
New Drug Approvals Are the Wrong Metric for Cancer Policy Bishal Gyawali, MD, PhD, has disclosed the following relevant financial relationship: Received consulting fees from: Vivio Health
Medscape Oncology, March 19, 2024
At ASCO, the Cancer Community Hyped the Wrong Trial Oncologist Bishal Gyawali, MD, PhD, highlights concerns surrounding which trials the oncology community is choosing to celebrate.
Medscape Oncology, June 29, 2023
What's Wrong With Cancer Clinical Trials? Look at Olaparib Oncologist Bishal Gyawali, MD, PhD, discusses problematic reporting of olaparib trials.
Medscape Oncology, June 01, 2023
The CodeBreaK Trial: We Broke the Code in More Ways Than One Oncologist Bishal Gyawali, MD, PhD, discusses how the core goals of drug development can get lost in the design and interpretation of the drug trial results.
Medscape Oncology, April 26, 2023
Why Is the FDA Granting Regular Approvals Prematurely? Oncologist Bishal Gyawali discusses how the number of drugs being given full FDA approval based on surrogate endpoints is on the rise.
Medscape Oncology, November 18, 2022
A Controversial Trial: Exposing Misunderstandings of NordICC Bishal Gyawali, MD, PhD, tries to bring clarity to the debate surrounding the controversial trial.
Medscape Oncology, October 14, 2022
The Great Irony of Modern Oncology: Immunotherapy's Imprecision Bishal Gyawali, MD, PhD, explores why immunotherapy and precision medicine in cancer care are incompatible.
Medscape Oncology, August 30, 2022
Attending ASCO in Person This Year? Remember These 14 Tips Bishal Gyawali, MD, PhD, provides guidance on how to get the most out of the upcoming ASCO meeting.
Medscape Oncology, May 12, 2022
Cancer Groundshot: From Blog Post to ASCO Session Bishal Gyawali, MD, PhD, looks at the rise of the cancer groundshot.
Medscape Oncology, April 20, 2022
Racism in Medicine: But Where Do You Really Come From? Bishal Gyawali, MD, PhD, looks at the pervasiveness of racism in medicine, and how misunderstanding can come into play.
Medscape Oncology, January 28, 2022
The FDA Should Listen to Its Own Evidence on Surrogate Markers Dr Gyawali explores the limited evidence to justify FDA drug approvals based on surrogate markers.
Medscape Oncology, November 12, 2021
Early Cancer Drug Results: Are We Celebrating Too Soon? How we can spot limitations in new clinical trial findings.
Medscape Oncology, September 10, 2021
FDA's Accelerated Approval Pathway Is Broken Have recent decisions by the FDA's Oncologic Drugs Advisory Committee undermined its credibility with patients and oncologists?
Medscape Oncology, August 04, 2021
How Do You Tell Someone Over the Phone That They're Dying? Forced to deliver the worst news possible over the telephone, oncologist Bishal Gyawali experienced the limitations of virtual healthcare.
Medscape Oncology, January 12, 2021
Discussing Patients' Private Lives for Better Cancer Care Helping cancer patients manage their fears and anxieties may have a better quality-of-life benefit than most marginal cancer drugs, argues Dr Bishal Gyawali.
Medscape Oncology, December 18, 2020
Where Is the Evidence for Supportive Oncology? If managing complications and side effects is the majority of what oncologists do, why isn't it supported with robust evidence, asks Dr Bishal Gyawali.
Medscape Oncology, October 29, 2020
Virtual ASCO Levels the Playing Field for Oncologists Everywhere Like everything in oncology, a virtual ASCO meeting is a tradeoff between benefits and disadvantages. But it may be a big win for oncologists in resource-strapped settings, argues Dr Bishal Gyawali.
Medscape Oncology, May 22, 2020
Lessons on COVID-19 From Low-Income Countries Physicians in lower-income countries routinely face the logistic difficulties and constrained resources now seen in first-world countries as a result of the coronavirus pandemic.
Medscape Oncology, March 26, 2020

No Results